Background. Delay of hematopoietic stem cell transplantation (HSCT) has been suggested if upper respiratory tract infection (URTI) due to respiratory syncytial virus (RSV) occurs in transplantation candidates, but the efficacy of this strategy in preventing posttransplantation RSV infection is unknown.
Respiratory syncytial virus (RSV) is the major cause of viral lower respiratory tract infection worldwide. Primary infection in infants is associated with lower respiratory tract involvement, whereas older children and adults generally develop mild upper respiratory illness. However, all immunocompromised patients are at high risk for severe lower respiratory tract disease, which often presents as interstitial pneumonia [1, 2] . RSV pneumonia is associated with high morbidity and mortality after hematopoietic stem cell transplantation [3] . Although it is known that RSV upper respiratory tract infection (URTI) early after transplantation has a high risk of progression to pneumonia, there are limited data regarding the natural history of pretransplantation RSV infection. The efficacy of delaying transplantation to prevent posttransplantation RSV infection is unknown. Pretransplantation RSV infection appears to be benign in selected hematopoietic stem cell transplantation (HSCT) situations, such as autologous transplantation for multiple myeloma treated with melphalan [4, 5] . However, it is difficult to define which patients will have high risk of progression.
This analysis was performed to evaluate the strategy of delaying HSCT in transplantation candidates after diagnosis of laboratory-proven RSV infection. Until recently, this was the strategy used at Fred Hutchinson Cancer Research Center (FHCRC; Seattle, WA). Transplantation was delayed until symptoms ceased and the result of a subsequent RSV test was negative. The effectiveness of this delay strategy in preventing posttransplantation RSV infection has not been evaluated. Potential disadvantages of delay before transplantation include progression of the patient's underlying disease and logistical issues regarding donor and patient availability. Our main objectives were to evaluate the outcomes of pretransplantation RSV infection in transplant recipients for whom HSCT was delayed and to determine the rate of RSV infection after transplantation. We also sought to assess the extent of progression of underlying disease during the delay, to analyze the effect of preemptive ribavirin therapy administered before transplantation, and to compare outcomes in patients who received nonmyeloablative versus myeloablative conditioning regimens.
PATIENTS, MATERIALS, AND METHODS

Patients.
The Institutional Review Board at FHCRC approved the study. The FHCRC VAX database was used to identify all HSCT candidates who had positive RSV test results before undergoing HSCT. The study period included patients who underwent transplantation during the period of June 1987 through December 2000. Charts for identified patients were reviewed, and the following data were extracted: the patient's demographic characteristics, HSCT protocol, RSV information (dates of tests, methods of testing, clinical description, and outcome of infection), treatment received and length of delay to transplantation, and clinical evidence of underlying disease progression and peripheral blast counts (for leukemic patients) during the delay period.
Virology. The policy of FHCRC during this time period was to obtain a surveillance sample for RSV testing for patients who presented with symptoms of URTI before transplantation. After transplantation, patients provided samples for tests for respiratory viruses only if they developed symptomatic URTI or lower respiratory tract infection. Bronchoalveolar lavage (BAL) samples, biopsy samples, nasopharyngeal (NP) washes, NP swabs, or oropharyngeal swab samples were tested for RSV by conventional tube culture, shell vial centrifugation culture, or direct fluorescent antibody (DFA) testing [6] . For culture, 3 systems (rhesus monkey kidney, A-259, and human foreskin fibroblasts) were used, and specimens were maintained for 10 days. For shell vial assays, 0.25-0.3-mL specimens were inoculated into vials containing a cover slip with an A-259 monolayer by means of standard methods. After centrifugation at low speed (700 g) for у40 min, cover slips were incubated for 2-4 days. Staining was performed with fluorescein isothiocyanate-labeled anti-RSV mouse monoclonal antibodies (Bartels). A similar procedure was used for DFA detection of RSV from fixed cells from NP and BAL specimens [6] .
Definitions. URTI was defined as the presence of nasal congestion and/or rhinorrhea in the absence of lower tract symptoms, with a clear or unchanged chest radiograph. Lower respiratory tract infection or possible pneumonia was defined as the presence of the following characteristics: clinical findings, including hypoxia, wheezing, and crackles at physical examination; or evidence on a chest radiograph of new pulmonary infiltrates. Pneumonia was considered to be proven if the chest radiograph had evidence of new infiltrates and BAL samples were positive for RSV. Transplant day 0 refers to the day on which marrow or stem cells were transferred. Study patients had 1-3 "day 0s," depending on transplantation regimen. Days before transplantation are referred to with a minus sign (e.g., day Ϫ4), and days after transplantation are indicated with a plus sign (e.g., day +4).
RSV treatment.
Aerosolized ribavirin was provided preemptively for pretransplantation treatment of RSV URTI at the discretion of the attending physician. There was no standard treatment protocol for use of ribavirin for RSV infections during the study period. The typical treatment regimen consisted of 6 g per day divided into 3 doses, administered over 2 h for 5-7 days. RSV pneumonia was treated the same way, with or without intravenous immunoglobulin (IVIG).
Statistical methods. Two-sided Fisher's exact test was used to compare outcomes of RSV pneumonia and death between groups of patients. Survival of inpatients with and without pretransplantation RSV infection was analyzed by the KaplanMeier method, and proportions were compared using the logrank test.
RESULTS
Patient Characteristics and Delay of Transplantation
Thirty-seven candidates for HSCT with pretransplantation RSV URTI were identified. The median age was 32 years (range, 0.5-63.8 years; table 1). The underlying disease was in relapse or advanced stage in 23 patients (62%). Thirteen patients (35%) received autologous transplants. Thirty-two patients (86.5%) received conventional conditioning; 5 patients (13.5%) were treated with a nonmyeloablative conditioning regimen.
RSV URTI was diagnosed before start of conditioning in 31 of 37 patients. In the other 6 patients, RSV URTI was diagnosed after start of conditioning. HSCT was delayed secondary to RSV infection for a total of 34 patients (figure 1). The median length of delay between a first RSV-positive test result to the date of transplantation was 35 days (range, 9-199 days). Two patients returned to homes out of state during the waiting period. The length of delay was generally determined by duration of viral shedding. Within 14 days after an initial positive RSV test result, 78% of results of subsequent virologic tests were negative. Eighty-six percent of test results were negative among patients tested 15-28 days after an initial positive test result.
RSV Pneumonia
Patients with transplantation delay versus no delay. Six patients developed documented RSV infection after the start of conditioning for allogeneic HSCT (table 2). In 5 of the 6 patients, symptoms including congestion, rhinorrhea, wheezing, and cough were present at the start of conditioning. Symptom data for the sixth patient are not available. Three of the 6 patients received their transplant during the first half of the study period: patient 1 and 3 underwent transplantation in 1991, and patient 6 underwent transplantation in 1987 (table  2) . RSV infection was diagnosed a median of 4.5 days into the conditioning regimen (range, 2-5 days).
In 3 of the 6 patients, conditioning was halted, and transplantation was delayed (table 2). Patient 2 received ribavirin therapy for upper respiratory symptoms and recovered. The other 2 patients developed symptoms of possible pneumonia; patient 1 recovered without therapy, and patient 3 recovered after ribavirin therapy. HSCT proceeded as scheduled in the remaining 3 patients. Transplantation was not delayed in these individuals for the following reasons: (1) concern of prolonged neutropenia after cessation of total body irradiation due to poor marrow reserve from previous prolonged courses of chemotherapy, (2) persistent relapse at transplantation, and (3) delayed laboratory culture diagnosis of RSV infection. Of these 3 patients for whom transplantation was performed without delay, 2 developed proven RSV pneumonia. Despite ribavirin and IVIG therapy, patient 5 died of RSV pneumonia on posttransplantation day +8. Patient 4 improved after receiving ribavirin and IVIG therapy. This patient died on day +90 with clinical diagnoses of relapsed primary disease (nodular sclerosis Hodgkin disease), Streptococcus viridans bacteremia, Moraxella catarrhalis pneumonitis, and parainfluenza 3 pneumonitis. Patients with transplantation delay who developed RSV infection after HSCT. Two (6.5%) of 31 patients developed RSV infection early after transplantation (figure 1). The first patient (age, 3 years) provided a sample and was positive for RSV on days Ϫ32 and Ϫ28 and negative for RSV on day Ϫ21, resulting in a pretransplantation shedding period of 11 days. The patient started conditioning on day Ϫ8 and developed URTI symptoms on day Ϫ5. An NP swab specimen was collected on day Ϫ1; results of DFA were negative. However, RSV was detected by conventional and shell vial culture on day +4.
Aerosolized ribavirin therapy (2 g q.d.) was initiated on day +4, but the patient developed lower respiratory tract symptoms and proven RSV pneumonia. The dosage of ribavirin therapy was increased to 6 g per day divided into 3 doses on day +9, 3 doses of IVIG were provided, and the patient recovered from RSV infection by transplantation day +16. The second patient (age, 16 months) provided a sample for testing for RSV infection, was found to have a positive result on day Ϫ40, and shed virus for 7 days. This patient developed URTI symptoms on day +3, and RSV was isolated by shell vial culture on day +7. Despite developing possible pneumonia with wheezing and tachypnea, a BAL was not performed because of the patient's age and lack of family consent to the procedure. The patient's symptoms resolved with antiviral treatment including ribavirin (6 g q.d.) and 1 dose of RSV-specific immunoglobulin.
Overall, proven RSV pneumonia occurred in 1 of 34 patients in whom HSCT was delayed, compared with 2 of 3 patients for whom there was no delay ( ). When the 3 additional P p .01 persons with possible RSV pneumonia are included and analyzed with the group for which transplantation was delayed, there was still a trend toward more cases of RSV disease among patients without delay ( ). Fatal RSV pneumonia oc-P p .06 curred in 0 of 34 patients with HSCT delay, compared with 1 of 3 patients for whom there was no delay ( ). P p .08 
Status of Underlying Disease during Delay
Disease progression was assessed only in the 31 patients who had RSV infection diagnosed before the start of conditioning. Among these 31 patients, 13 were in remission at the time of the initial diagnosis of RSV infection, and none of these showed progression of underlying disease during the delay period. Eighteen of 31 patients were in relapse or advanced disease state at RSV diagnosis. Of the 18 patients, 2 (11%) exhibited evidence of possible progression of their primary disease during the delay period before transplantation. One of these patients had acute lymphocytic leukemia with refractory CNS relapse, which progressed during hospitalization for concomitant H aemophilus influenzae pneumonia at the time of initial RSV diagnosis. The patient recovered from these infections but died of fungal sepsis and cardiopulmonary failure 25 days after transplantation. The second patient had non-Hodgkin lymphoma with an abdominal mass that continued to enlarge during the pretransplantation diagnostic study and transplantation delay. This patient had RSV infection diagnosed on day Ϫ20 and shed virus for 7 days. After transplantation, the patient was discharged to hospice care secondary to refractory lymphoma.
Ribavirin Preemptive Therapy
Ribavirin was provided on the basis of the discretion of the patient's attending physician. Of the 37 patients, 6 (16%) received pretransplantation preemptive ribavirin therapy for a laboratory-confirmed RSV URTI. Patients who were selected for ribavirin treatment did not appear to differ in their underlying immune status from those who did not receive therapy.
One of 6 patients who received preemptive ribavirin for URTI symptoms developed proven pneumonia, compared with 2 of 31 patients who did not receive ribavirin for URTI symptoms ( ). When any pneumonia (possible or proven) is con-P p .42 sidered as the outcome, 2 of 6 patients treated with preemptive ribavirin developed pneumonia, compared with 4 of 31 who did not receive preemptive ribavirin ( ). P p .24
Myeloablative versus Nonmyeloablative Transplant
Of 37 patients in this study, 5 (13.5%) received transplants with nonmyeloablative conditioning regimens. Of the 5 patients, 3 received matched, related peripheral blood stem cell (PBSC) transplants; 1 received a matched, unrelated PBSC transplant; and 1 received a matched, unrelated bone marrow transplant. Four of the 5 patients developed pretransplantation RSV infection before conditioning and recovered without ribavirin therapy. The fifth patient (patient 2) developed RSV URTI during conditioning, the conditioning regimen was halted after 3 doses of fludarabine, and the patient received ribavirin therapy and recovered (table 2).
Probability of Survival
Kaplan-Meier curves were plotted to assess the effect of pretransplantation RSV infection on overall survival when compared with persons without pretransplantation RSV infection (figure 2). Between 1987 and 1994, the probability of survival in patients with preconditioning RSV infection ( ) was n p 31 close to 60%, similar to probability of survival in patients without pretransplantation RSV infection ( ) ( ). n p 4953 P p .53 Survival among hematopoietic stem cell transplant recipients with and those without pretransplantation respiratory syncytial virus (RSV) infection. Patients with pretransplantation infection are subdivided by timing of RSV infection (preconditioning vs. postconditioning). Results are shown for the entire study period (A) and by date of transplantation before (B) and after (C) 1994, when uniform prevention strategies for cytomegalovirus (ganciclovir) and fungal infections (fluconazole) were in place. Differences between the preconditioning groups and the RSV-uninfected groups were not statistically significant in any of the groups ( , , and for panels A, B, and C, P p .53 P p .34 P p .34 respectively).
Autologous transplant recipients with pretransplantation RSV infection (
) had a similar probability of survival, comn p 13 pared with all other autologous transplant recipients (n p ), during the entire study period ( ). When overall 1173 P p .56 outcome was examined in the more recent time period with optimized supportive care after HSCT (including use of ganciclovir and fluconazole prevention strategies [7, 8] ), there was no apparent difference in the survival rate, compared with the subgroup transplanted before 1994 ( ; figure 2) . P p .34
DISCUSSION
In this analysis, progression to RSV pneumonia was significantly less common among transplant candidates with pretransplantation RSV infection for whom HSCT was delayed than among those for whom transplantation was not delayed. There was also a trend toward increased risk of RSV-related death when transplantation was not delayed, and the overall outcome was poorer in patients among whom RSV infection occurred after the start of conditioning. The main reason transplantation was not delayed in 3 patients was that a laboratoryconfirmed diagnosis of RSV infection was unavailable before beginning conditioning (table 2 and figure 1 ). For the 6 patients with diagnosis after the start of conditioning, the timing of virologic diagnosis was a median of 4.5 days (range, 2-5 days) into the conditioning regimen. However, all 6 patients were symptomatic at the start of conditioning. Waiting for a laboratory-proven diagnosis to delay transplantation, rather than delaying on the basis of URTI symptoms, may thus have allowed respiratory symptoms to progress as the conditioning regimen was initiated.
Survival among patients in whom transplantation was delayed did not appear to be different from that of other transplant recipients transplanted during the same time period (figure 2) . Rates of posttransplantation RSV infection also did not seem to be increased. In a recent FHCRC study, the overall attack rate of RSV infection (URTI or pneumonia) in persons who had undergone HSCT after transplantation was 4.5%; the rate among patients who underwent transplantation during the winter RSV season was ∼10% [9] . Therefore, the posttransplantation infection rate of 6.5% in our analysis does not appear higher than the rate seen in patients who underwent transplantation without pretransplantation RSV infection.
The median length of delay from the initial diagnosis of RSV infection to transplantation was 1 month; viral shedding data observed in this study suggest that a delay of 4 weeks should be sufficient to provide a negative follow-up laboratory test result in most cases. Once transplant candidates have had an initial positive RSV test result, weekly testing of nasal wash specimens is appropriate. There was minimal progression of underlying disease in 2 (6.5%) of 31 patients during delay to transplantation. Although the numbers are small, these data suggest that progression of the patient's primary disease should be minimal during the recommended time period to delay transplantation.
The study has strengths and limitations. Strengths include a consistent delay policy based on laboratory-proven RSV infection, standardized supportive care, and the presence of a targeted surveillance system, which included evaluation of all patients with URTI and pneumonia for RSV infection. Limitations include the retrospective nature of the study and the nonrandomized design. There is a wide range of age in the study population and in patients who developed possible and proven pneumonia; however, the small cohort size prevents us from providing any interpretations regarding age and disease severity. Because of the limited numbers of patients and inconsistent use of ribavirin, our study is unable to adequately evaluate whether preemptive ribavirin therapy for RSV URTI may be used to shorten the duration of viral shedding. Further investigation is needed to evaluate whether there may be benefit from preemptive therapy with aerosolized ribavirin or palivizumab. Likewise, small numbers of patients who received nonmyeloablative transplants make interpretation of outcomes difficult. Recently, it has been demonstrated that, despite a high incidence of respiratory viral infections, low mortality was associated with posttransplantation respiratory viral infections in patients who received reduced-intensity conditioning regimens [10] . Further study is required to determine whether some patients, such as low-risk autograft recipients or some nonmyeloablative transplant recipients, can safely be transplanted in the presence of RSV URTI. For example, a recent study suggests that some autologous transplant patients may undergo transplantation with RSV infection [5] . However, our data suggest that delay of transplantation is advised when a traditional allogeneic myeloablative regimen is used, which may lead to prolonged lymphopenia. Severe lymphopenia has been described as an important risk factor for progression of respiratory viral infections [11, 12] .
The study cohort appears large enough to draw some conclusions. In patients with pretransplantation RSV URTI, delay of HSCT was associated with a lower risk of pneumonia than in patients without delay. Our data demonstrate that, if transplantation is delayed before the start of conditioning, there is no difference in mortality or in risk of acquiring posttransplantation RSV infection. Therefore, a strategy of delaying HSCT in transplantation candidates with pretransplantation RSV URTI appears to be safe and effective. Recent Centers for Disease Control and Prevention/American Society of Blood and Marrow Transplantation guidelines for preventing opportunistic infections among persons undergoing HSCT advise physicians to conduct active clinical surveillance for respiratory infection for all candidates undergoing conditioning therapy, including daily screening for signs and symptoms of an upper or lower respiratory tract infection [13] . It is recommended that the etiology of a URTI in an HSCT candidate undergoing conditioning therapy should be determined, if possible, before continuing to transplantation. Our study supports the recommendation that the conditioning regimen for transplantation candidates should be postponed when respiratory symptoms are present before the availability of laboratory evidence of viral infection, because even mild URTI symptoms (such as rhinorrhea, sore throat, and watery eyes) can cause progression to severe complications when patients undergo myeloablative conditioning therapy. The data appear to be solid for candidates of allogeneic donor transplantations in remission. In patients in relapse or advanced disease state, the risk of progression (11% in this study) must be balanced against the risk of progression of RSV infection. This risk is real in allogeneic transplant recipients but difficult to quantify. Future research should address the question of whether transplantation with nonmyeloablative conditioning regimens, alone or in combination with antiviral strategies, can be used for patients with active RSV infection or other respiratory viral infection.
